Codexis Inc News Today

EQS-News: BRAIN Biotech AG / Key word(s): PersonnelBRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes 29.05.2024 / 09:00 CET/CESTThe issuer is solely responsible for the content of this announcement.BRAIN Biotech AG announces the appointment of Erik de Vries a...

REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company...

REDWOOD CITY, Calif., May 22, 2024 -- Codexis, Inc. , a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 5-6,...

Codexis (NASDAQ:CDXS – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Benchmark in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $9.00 target price on the biotechnology company’s stock. Benchmark’s target price suggests a potential upside of 129.59% from the stock’s current […]

Q1 2024 Results May 2, 2024 We engineer enzymes Forward Looking Statements ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Codexis Inc. (CDXS) on Thursday reported a loss of $11.5 million in its first quarter.

Key Insights Given the large stake in the stock by institutions, Codexis' stock price might be vulnerable to their...

REDWOOD CITY, Calif., April 18, 2024 -- Codexis, Inc. , a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2024 on Thursday,...

Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platform...

Codexis, Inc. (NASDAQ:CDXS – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among analysts that have […]